• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Principal Accounting Officer Adamchak Mark

    3/18/25 6:45:45 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BNGO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Adamchak Mark

    (Last) (First) (Middle)
    C/O BIONANO GENOMICS, INC.
    9540 TOWNE CENTRE DRIVE, SUITE 100

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Bionano Genomics, Inc. [ BNGO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Principal Accounting Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $3.47 03/14/2025 A 3,029 (1) 03/13/2035 Common Stock 3,029 $0 3,029 D
    Explanation of Responses:
    1. 100% of the shares subject to the option vest on the one-year anniversary of the grant date.
    Remarks:
    /s/ Jonathan V. Dixon, Attorney-in-Fact 03/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BNGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNGO

    DatePrice TargetRatingAnalyst
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    9/10/2024Buy → Neutral
    BTIG Research
    1/5/2023$4.00Sector Outperform
    Scotiabank
    12/12/2022$3.50Buy
    BTIG Research
    7/18/2022$12.00Outperform
    Oppenheimer
    More analyst ratings

    $BNGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b

      5/7/25 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced the publication in the American Journal of Hematology of expert recommendations from the International Consortium for Optical Genome Mapping (ICOGM) for the integration of OGM as a standard-of-care (SOC) cytogenetic assay for diagnostic workflows in various clinical settings. Nineteen (19) experts from the ICOGM, representing relevant multidisciplinary fields, conducted an in-depth review of the classification of hematolymphoid malignancies usin

      5/2/25 9:30:12 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping (OGM) can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation (SV) linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at Radboud University Medical Center in the Netherlands, the study provides one of the most comprehensive evaluations to date of OGM as a single workflow for characterizing large repeat expansions. Researchers evaluated 85 subjects containing known pathogenic expansions in three

      4/23/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

      SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

      2/13/24 5:00:51 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

      SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

      7/7/23 4:35:55 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

      SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

      1/30/23 4:03:23 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by General Counsel Dixon Jonathan V.

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:55 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Principal Accounting Officer Adamchak Mark

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:45 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Holmlin R. Erik covered exercise/tax liability with 198 shares, decreasing direct ownership by 10% to 1,783 units (SEC Form 4)

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:35 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Bionano Genomics Inc.

      DEFA14A - Bionano Genomics, Inc. (0001411690) (Filer)

      4/28/25 4:17:17 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Bionano Genomics Inc.

      DEF 14A - Bionano Genomics, Inc. (0001411690) (Filer)

      4/28/25 4:15:40 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form PRE 14A filed by Bionano Genomics Inc.

      PRE 14A - Bionano Genomics, Inc. (0001411690) (Filer)

      4/18/25 4:15:28 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Leadership Updates

    Live Leadership Updates

    See more
    • LeddarTech Appoints Chris Stewart as Chief Financial Officer

      QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial

      11/15/23 12:07:00 AM ET
      $BNGO
      $PRSR
      $TSLA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Blank Checks
      Finance
    • Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

      SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe

      8/14/23 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l

      11/10/22 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bionano Genomics downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral

      11/15/24 7:40:01 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics downgraded by BTIG Research

      BTIG Research downgraded Bionano Genomics from Buy to Neutral

      9/10/24 7:37:53 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Scotiabank initiated coverage on Bionano Genomics with a new price target

      Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00

      1/5/23 7:29:54 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Financials

    Live finance-specific insights

    See more
    • Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b

      5/7/25 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

      SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 31st, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/5v2s5x5r Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website

      3/14/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024

      SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 13th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/dmabxin9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h

      11/7/24 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials